A Multicenter, Randomized, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF) and Safety in Subjects With Secondary Progressive Multiple Sclerosis.
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Baminercept (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors Biogen
- 31 Mar 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 02 Sep 2010 New trial record